CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On June9, 2017, CareDx, Inc. (the Company) issued a press release
announcing its financial results for the quarter ended March31,
2017. A copy of the press release is attached hereto as
Exhibit99.1 and is incorporated herein by reference.
The information in this Item2.02, including the press release
attached hereto as Exhibit99.1, is intended to be furnished under
Item2.02 and Item9.01 of Form8-K and shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits.
| ExhibitNo. | Description | |
| 99.1 | Press Release issued by CareDx, Inc. dated June9, 2017. |
About CAREDX, INC. (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
